^
    Back
    Association details:
    Biomarker:BCOR F1106Tfs*5
    Cancer:Adenoid Cystic Carcinoma
    Drug:Focus V (anlotinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Anticancer Drugs
    Title:

    Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma

    Published date:
    07/30/2021
    Excerpt:
    ...two novel BCL-6 corepressor (BCOR) mutations (p.F1106Tfs*5 and p.L1524Hfs*8)....study presented the first case of perianal ACC with multiple pulmonary metastases and particular BCOR mutations, who presented a durable response to eribulin and anlotinib, providing a potential therapeutic option for advanced refractory ACC.
    Secondary therapy:
    MORAb-202
    DOI:
    10.1097/CAD.0000000000001171